Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins

Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins

US Patent 9072757 · Granted Jul 7, 2015

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tire comprising a textured tread2024
Composition and methods used during anti-HIV treatment2017
Composition and methods used during anti-HIV treatment2017
Method for analyzing D4Z4 tandem repeat arrays of nucleic acid and kit therefore2016
Suspension system for vehicle and tire for vehicle2015
Exon skipping therapy for dysferlinopathies2013
HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatme2013
HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatme2013
HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatme2013
Human cathepsin L2 protein, gene encoding said protein and use thereof2004